Retatrutide Clinical Trial Results: Phase 2 Study Shows Superior Weight Loss in Diabetes Patients
Retatrutide represents breakthrough peptide therapy as a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. This randomized c...
New England Journal of MedicineIF: 176.1
retatrutideclinical trialdiabetesweight loss+1 more